Prenetics Global Limited

NASDAQ:PRE

Medical - Diagnostics & Research

Healthcare
$10.35 +2.19%

+$0.43 today

Market cap
$185.61M
Beta
0.24
P/E (TTM)
-4.9
EPS (TTM)
-$4.18
52W Low $7.18High $23.63

Volume 1.58M

Average 0.22M

PRE Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Prenetics Global LimitedNASDAQ: PRE

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $1.24M rose 12.8% year over year, ahead of the -98.0% change in trailing-twelve-month stock-based compensation.

Context

  • Stock-based compensation amounted to 0.0% of revenue in FY2025, down 39.1 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +12.8% holds above the trailing-twelve-month pace of -98.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.24M+141.6% QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMMar 2026
$141K-98.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.8%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Stock-Based Compensation vs competitors

How PRE compares with its peers on the latest reported figures

  • PRE's LTM Mar 2026 stock-based compensation of $141K is the smallest of the 11 companies compared; the peer median is $6.51M.
  • Its year-over-year change of -98.0% is the lowest of 11, against a peer median of -6.4%.
  • Stock-based compensation amounts to 0.1% of revenue for PRE, versus a peer median of 16.4%.
PRE Competitors Peer median
Stock-Based Compensation for PRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATLNAtlantic International Corp.LTM Dec 2025$36.14M -20.0%+420.1%8.3%
OSUROraSure Technologies, Inc.LTM Mar 2026$11.45M -1.6%-90.4%10.1%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$9.98M +67.1%+191.7%22.2%
CDXSCodexis, Inc.LTM Mar 2026$8.67M -29.5%-12.8%11.1%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$7.48M -39.0%-34.0%21.6%
PROFProfound Medical Corp.LTM Mar 2026$5.55M +98.0%+9.0%29.4%
STIMNeuronetics, Inc.LTM Mar 2026$5.4M -5.3%-7.8%3.6%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$2.9M -7.5%-5.6%98.2%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$2.4M +50.7%-39.5%123.1%
MXCTMaxCyte, Inc.LTM Mar 2026$706K -76.8%—2.2%
PREPrenetics Global LimitedLTM Mar 2026$141K -98.0%—0.1%
Peer median (excluding PRE) $6.51M-6.4%-7.8%16.4%

Competitors are the stored peer set for PRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(174.02M)(190.45M)(64.78M)(49.81M)(52.7M)
Depreciation & Amortization7.35M7.54M7.79M5.93M3.78M
Deferred Income Tax3.73M7.15M(385.84K)(7.87M)0
Stock-Based Compensation22.49M31.58M10.59M11.98M0
Change in Working Capital(6.59M)(33.76M)24.21M1.97M6.62M
Accounts Receivables(24.06M)6.97M37.63M(428K)(529K)
Inventory(2.33M)1.26M(1.73M)1.32M(3.38M)
Accounts Payables(3.46M)(2.63M)(5.62M)(4.68M)4.91M
Other Working Capital23.26M(39.36M)(6.08M)5.75M5.62M
Other Non-Cash Items160.45M192.46M8.8M8.93M20.48M
Operating Cash Flow13.42M14.51M(13.76M)(28.87M)(21.81M)
Capital Expenditures(11.41M)(6.34M)(911.81K)(1.07M)(208K)
Acquisitions (Net)0(3.42M)021.65M37.78M
Purchases of Investments(10M)(39.92M)(26M)(129K)(20M)
Sales of Investments03M19.92M16M0
Other Investing Activities(3.47M)531.99K(76.52M)2.02M1,000K
Investing Cash Flow(22.02M)(46.14M)(82.95M)38.54M(35.79M)
Debt Repayment(1.3M)(1.88M)(3.23M)(2.56M)40.15M
Common Stock Issued0116.86K2.17K02K
Common Stock Repurchased0(661.52K)(1.23M)(577K)0
Dividends Paid00000
Other Financing Activities4.65M145.86M(241.5K)(203K)(2.61M)
Financing Cash Flow29.32M143.32M(4.7M)(3.34M)37.54M
Effect of Forex Changes87.21K(317.47K)467.93K221K(65K)
Net Change in Cash20.8M111.37M(100.95M)6.55M(20.12M)
Free Cash Flow2M8.17M(14.68M)(29.94M)(22.02M)

Prenetics Global Limited

NASDAQ:PRE

Intrinsic Alpha fair value

Locked

Current Price

$10.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.